Amniotic Fluid Biomarkers for Congenital CMV Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective early detection of fetal cytomegalovirus (CMV) infection during gestation and fail to predict symptomatic disease, leading to inadequate prevention and treatment strategies.
Innovation Solution
Detection of biomarkers such as sFlt1, cmvIL-10, and altered cellular proteins in amniotic fluid and maternal sera, using reagents that specifically bind to CMV-associated markers, allows for early diagnosis, prediction of fetal disease, and assessment of therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If maternal CMV IgG avidity assays are used to identify women at risk for primary infection, then women at risk can be identified, but fetal infection and symptomatic disease cannot be reliably predicted
Solution Approach 1:
The patent introduces amniotic fluid biomarkers (sFlt1, cmvIL-10, and other cellular proteins) as intermediary substances that mediate between maternal infection status and fetal infection detection. These biomarkers serve as direct indicators of fetal CMV infection and placental function, bridging the gap between maternal serology and fetal outcome prediction.
Solution Approach 2:
The patent measures multiple parameters in amniotic fluid including sFlt1 concentration, cmvIL-10 concentration, and ratios of these biomarkers. By monitoring changes in these parameters over time and comparing them to established thresholds, the system achieves precise prediction of fetal infection and symptomatic disease outcomes.
2Loss of time
If current diagnostic methods are used, then maternal infection status can be assessed, but early detection of fetal infection during gestation is not achieved
Solution Approach 1:
The patent enables preliminary detection of fetal infection by measuring biomarkers in amniotic fluid during the second or third trimester, well before birth. This preliminary action allows for early identification of infected fetuses, enabling timely intervention and treatment planning while the fetus is still in utero.
3Measurement precision
If no specific fetal infection markers are used, then diagnostic simplicity is maintained, but prediction of symptomatic disease is not achieved
Solution Approach 1:
The patent segments the diagnostic approach into multiple independent biomarker measurements (sFlt1, cmvIL-10, and other cellular proteins) that can be assessed separately and then integrated. This segmentation allows for systematic evaluation of different aspects of fetal infection and placental function, improving predictive accuracy while maintaining assay manageability through modular testing.
Solution Approach 2:
The amniotic fluid biomarker panel serves multiple functions: detecting fetal CMV infection, assessing placental health, predicting symptomatic disease outcomes, and monitoring response to treatment. This multi-functionality consolidates multiple diagnostic needs into a single comprehensive testing approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of congenital CMV infection, prediction of fetal disease, and evaluation of treatment efficacy, facilitating timely intervention and improved maternal and fetal outcomes.
Implementation Method 1
contacting the biological sample with reagents that specifically bind to at least one CMV-associated marker
Data Source
AI summary
The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals.